Redefining Regulatory Proof: The End of the Two‐Trial Paradigm
Jean‐Christophe Lega, Steeve Provencher, Bruno Falissard, Clara Locher, Matthieu Roustit, Arthur Gougeon, Rémy Boussageon, Sylvie Chevret · 2026
Read Redefining Regulatory Proof: The End of the Two‐Trial Paradigm by Jean‐Christophe Lega, Steeve Provencher, Bruno Falissard, Clara Locher, Matthieu Roustit, Arthur Gougeon, Rémy Boussageon, Sylvie Chevret (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13472732.txt.
Description
Lega and co-authors argue against the United States' move to accept one main trial as the default proof for drug approval, in a 2026 commentary. The two-trial tradition treated independent replication as the bedrock of regulatory evidence. The authors describe the shift as a move from replication to coherence as the standard of sufficiency. Because American rules shape global drug development, the change will travel.
Faster access and lower cost are real gains, they grant. But the statistical case, they argue, skips context such as how plausible a claim is beforehand and how much power a single trial holds. Later real-world evidence rarely restores what replication gave. Without guards, they warn, evidence bars will drift unevenly and assessment bodies will struggle to discriminate.
Catalog record
| CREATOR | Jean‐Christophe Lega, Steeve Provencher, Bruno Falissard, Clara Locher, Matthieu Roustit, Arthur Gougeon, Rémy Boussageon, Sylvie Chevret |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |